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Introduction: Up to 30% of individuals treated with antiretroviral therapy (ART) during chronic 
HIV fail to recover CD4 counts to >500 cells/mm3 and up to 10% have quantifiable HIV RNA in 
cerebrospinal fluid (CSF), termed CSF escape, despite plasma viral suppression < 50 copies/mL. 
Previous studies have shown that ART initiation in the earliest stage of identifiable infection, 
acute HIV infection (prior to antibody seroconversion), may limit viral reservoir establishment 
and systemic immune activation and may improve clinical outcomes. We investigated the 
frequency, associations, and outcomes of suboptimal CD4 recovery (Project 1) and CSF escape 
(Project 2) after ART started during acute HIV infection (AHI). 
Methods: Thai participants with laboratory-confirmed diagnosis of AHI (Fiebig stages I to V) 
were started immediately on ART and followed longitudinally with blood sampling, 
neuropsychological and neurobehavioral testing, and optional lumbar puncture. For Project 1, 
participants with ≥48 weeks of documented HIV RNA <50 copies/mL were stratified by CD4 
count at latest study visit to suboptimal recovery (SR; CD4<350 cells/mm3), intermediate 
recovery (IR; 350≤CD4<500), and complete recovery (CR; CD4≥500). To assess determinants 
of CD4 recovery, clinical and laboratory parameters were evaluated at pre-ART baseline and 
latest study visit. Additional inflammatory and neurobehavioral endpoints were examined at 
baseline and 96 weeks. For Project 2, participants who underwent blood sampling and optional 
CSF sampling at weeks 24 and 96 were assessed for CSF escape. HIV RNA was quantified using 
Roche Amplicor and COBAS TaqMan assays with a lower limit of quantitation of 20-50 
copies/mL in plasma and 80 copies/mL in CSF. Participants with quantifiable CSF HIV RNA 




Results, Project 1: Of 304 participants (96% male, median 26 years old) evaluated after median 
144 (range 60-420) weeks of ART initiated at median 19 days (range 1-62) post-exposure, 3.6% 
(n=11) had SR, 14.5% (n=44) had IR, and 81.9% (n=249) had CR. Degree of CD4 recovery 
occurred early following ART. Timing of ART initiation by Fiebig stage did not affect CD4 
count during treatment. Pre-ART CD4 count in SR compared to CR participants was 265 vs 411 
cells/mm3 (p=0.002). Following ART, the CD8+ T cell count (p=0.001) and CD4/CD8 ratio 
(p=0.047) were lower in SR compared to CR participants. Compared to the CR group at week 
96, the combined SR and IR groups had higher sCD14 (p=0.008) and lower IL-6 (p=0.04) in 
plasma, without differences in neuropsychological or psychiatric indices. After adjusting for 
duration of ART, baseline HIV-RNA, and baseline CD4 count, odds of CD4 recovery < 500 
cells/mm3 were higher in those with baseline CD4/CD8 ratio < 1 (odds ratio 3.2, p=0.01), on-
ART CD4/CD8 ratio < 1 (odds ratio 2.4, p=0.007), and on-ART CD8 count < 500 cells/mm3 
(odds ratio 3.1, p=0.0005). 
Results, Project 2: 204 participants had paired blood and CSF sampling in at least one visit at 
baseline, week 24, or week 96. The participants were 98% male (199/204) with median age 26 
years and baseline Fiebig stage 3 (96/204, 47%), CD4 count 386 cells/mm3, and plasma HIV 
RNA 5.87 log10 copies/mL. ART was started at a median of 19 days post estimated infection. At 
baseline, 126/165 participants (76%) had quantifiable CSF HIV RNA (median 3.13 log10 
copies/mL). At week 24 (n=90), two participants (2%) had quantifiable CSF HIV RNA, with one 
case of CSF escape identified with plasma HIV RNA < 50 copies/mL and CSF HIV RNA 2.50 
log10 copies/mL. At week 96 (n=55), one participant (2%) had quantifiable CSF HIV RNA, 
which did not meet criteria for CSF escape. The two other cases of quantifiable CSF HIV RNA 




with efavirenz, tenofovir, and lamivudine and had a CD4 count of 840 cells/mm3 and CSF WBC 
and CSF protein of 4 cells/mm3 and 30 mg/dL. His MRI at week 24 showed a small nonspecific 
T2/FLAIR hyperintense focus in the right high frontal white matter. He did not have a lumbar 
puncture performed at baseline nor at subsequent visits. 
Conclusions: Despite immediate and sustained treatment in AHI, suboptimal CD4 recovery is 
observed in rare individuals, associated with low pre-ART CD4 count as well as persistent low 
CD8 count and CD4/CD8 ratio during treatment. While levels of CSF HIV RNA in untreated 
AHI are high, initiating treatment during AHI results in a very low rate of CSF escape in the first 
two years of ART. The low rate of CSF escape may also be impacted by high levels of adherence 
to ART in this cohort or the short duration of ART. Longitudinal monitoring will be required to 
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HIV Infection in the Era of Antiretroviral Therapy 
Throughout its storied impact on human health, the human immunodeficiency virus (HIV) 
epidemic has uniquely intersected with issues of stigma, mental health, sexual identity and 
expression, and poverty, and once spelled near-inevitable morbidity and mortality for individuals 
already marginalized by their communities. Now, more than 60% of people living with HIV are 
receiving antiretroviral therapy (ART), transforming HIV infection into a chronic manageable 
condition affecting an estimated 37.9 million people worldwide [1]. Substantial progress has been 
made in reducing HIV transmission, improving screening, and expanding access to ART. 
However, the number of people living with HIV likely will continue to increase in more than 100 
countries, as estimated by incidence-prevalence ratios [1]. Thus, with approximately 23.3 million 
people on ART and growing, there is considerable interest in long-term outcomes of people on 
virally suppressive ART. Chronic complications of treated HIV infection include systemic 
immune dysregulation and inflammation, accelerated cardiovascular disease, insulin resistance, 
reduced bone mineral density, chronic kidney disease, and HIV-associated neurocognitive 
disorders (HAND) [2-5]. Notably, this should be distinguished from chronic complications 
thought to be related to long-term use of certain ART medications [5]. In particular, this section 
will draw attention to the persistence of immune dysregulation, neurocognitive impairment, and 
HIV reservoirs, even in the era of ART and in the setting of plasma viral suppression. 
Early in the HIV epidemic, even before it was identified as the cause of acquired 
immunodeficiency syndrome (AIDS), immune activation was described in tandem with very low 
CD4+ T cell counts in the first case reports of AIDS [6]. Lymphocytes were found to have high 





more rapid disease progression [7, 8]. Likewise, the markers of innate immune activation neopterin 
and ß2-microglobulin were found to be elevated in untreated HIV infection, which in particular 
correspond to monocyte and macrophage activation, respectively [8, 9]. Inflammatory and 
coagulation indices are also elevated in untreated HIV infection, such as interleukin-6, D-dimer, 
C-reactive protein, and soluble CD14, and additionally predict morbidity and mortality [10-12]. 
Even with effective plasma viral suppression on ART, T cell activation persists [13], and 
inflammatory indices are elevated and predict non-AIDS-defining adverse events independent of 
pre-ART nadir and recent CD4+ T cell count [14, 15].  
Mechanistically, many factors may contribute to persistent immune dysregulation in 
treated HIV infection. Gut mucosal CD4+ T cells are rapidly depleted in early HIV infection, and 
the resultant mucosal inflammation damages the epithelial barrier of the gastrointestinal tract 
leading to intestinal microbial translocation [16]. Both intestinal CD4+ T cell depletion and 
microbial translocation are thought to contribute to persistent immune activation [17, 18]. Also 
occurring early in infection, HIV replication in lymphoid tissues results in collagen deposition and 
fibrosis, likely due to increased T regulatory cell activity and TGF-ß secretion. Lymphatic fibrosis 
contributes to poor CD4+ T cell reconstitution and immune dysregulation [19, 20]. Co-infection 
with pathogens such as cytomegalovirus may also be implicated in residual inflammation in treated 
HIV infection [21, 22]. Beyond T cell activation, other findings of T cell dysregulation have been 
described in HIV infection, which are only partially ameliorated with ART. T cell exhaustion is 
marked by upregulation of inhibitory receptor programmed death 1 (PD-1), results in impairment 
of T cell activity, including reduced cytokine secretion, proliferative capacity, and cytotoxic 
effector function [23], and occurs in HIV-specific CD8+ T cells in treatment-naïve participants 





HIV infection [23, 25]. Commencement of ART only partially downregulates these markers of T 
cell exhaustion [26]. CD8+ T cells are not only activated and exhausted in untreated and treated 
HIV infection, their population is also markedly expanded [27]. The coalescence of CD4+ T cell 
depletion and CD8+ T cell expansion is captured by the metric of the CD4/CD8 ratio, which is 
increasingly recognized as a measure of immune activation that predicts worse clinical outcomes 
[28]. Ultimately, inflammation, coagulopathy, and immune activation in ART-suppressed HIV 
infection are multifactorial processes that contribute to an elevated risk of non-AIDS-related 
morbidity and mortality. Importantly, immune dysregulation has been linked to poor CD4+ T cell 
recovery even while on long-term ART [13, 29], a main subject of this thesis. 
HIV-associated dementia (HAD) occurred in up to 30% of patients with AIDS-defining 
illnesses prior to the advent of ART. However, with the widespread use of ART, the burden of 
HAD has substantially decreased while the burdens of milder forms of HAND have increased, 
including asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder 
(MND) [2, 30]. This occurs despite the widespread availability of ART in resource-rich settings 
and despite effective virological suppression systemically and in the central nervous system 
(CNS). Interestingly, neurocognitive impairment seems to be primarily in the motor, cognitive, 
and verbal domains in the pre-ART era, and in memory and executive function in the ART era [2]. 
The increased prevalence of HAND even in the era of ART raises the question of whether ART is 
effective at suppressing viral replication in the central nervous system (CNS) or modulating 
neuroinflammation, or whether there are other mechanisms driving persistent neurocognitive 
impairment including irreversible CNS injury prior to ART initiation, ß-amyloid deposition in the 
brain, neurovascular injury, or antiretroviral neurotoxicity [2]. Generally, most studies appear to 





described and recognized [31]. It is still unknown whether ART is sufficient to prevent HAND, 
though very early treatment initiation may prevent it in a majority of individuals [4, 32]. Because 
milder HAND remains prevalent in people living with HIV and on ART, specific treatment for 
HAND can be considered in these individuals including antiretroviral switch, treatment 
intensification, and potentially newer drugs under investigation such as cenicriviroc and 
natalizumab [4, 33]. 
Chronic complications of treated HIV infection, including immune dysregulation and 
HAND, may stem from persistence of HIV reservoirs, which are not eradicated by long-term ART. 
HIV reservoirs are established early in infection, may be maintained chronically by ongoing HIV 
replication, and are thought to predominantly come from resting memory CD4+ T cells that harbor 
latent proviral DNA [34, 35]. Other important anatomic reservoirs include the genital tract, the 
gastrointestinal tract, lymphoid tissues (including thymus, gut-associated lymphoid tissue, and 
lymph nodes), and the CNS. ART may reduce, but does not completely eliminate, reservoirs as 
measured by total HIV DNA load [36]. Lamers et al demonstrated measurable HIV DNA is present 
in a majority of autopsy tissues, including brain, sampled in various anatomical sites of individuals 
on ART with low or undetectable viral load prior to death [37]. There may be some effect of timing 
of ART initiation upon HIV reservoir size. Earlier treatment in perinatal HIV infection is 
associated with smaller peripheral blood proviral reservoir size in adolescence [38]. Likewise, 
treatment during acute HIV infection reduces systemic HIV reservoirs compared to individuals 
treated for chronic infection. Conversely, progression throughout the stages of acute HIV infection 
associates with increased HIV reservoir seeding [39]. Specifically within the CNS compartment, 
early treatment during acute infection has not yet proven to reduce CNS reservoir size, though 





immune responses in CSF [40]. Cerebrospinal fluid (CSF) escape of HIV, another main subject of 
this thesis, describes a discordance of detectable CSF HIV RNA alongside undetectable plasma 
HIV RNA, may be an indicator of active viral replication from CNS reservoirs, and is described 
later in further detail [41]. Altogether, despite ART, HIV infection remains persistent in the form 
of difficult-to-eradicate reservoirs in various anatomical compartments. Though HIV remission 
has been achieved to date in two individuals via hematopoietic stem cell transplant [42, 43], 
reservoirs represent a chronic disease burden for the vast majority of people living with HIV. 
Acute HIV Infection: The Earliest Events 
Acute HIV infection (AHI) describes the earliest detectable stages of HIV infection, when 
HIV serology remains non-reactive or inconclusive yet viral replication is detectable in tissue and 
blood [44]. After exposure and transmission, HIV replicates in the mucosa, submucosa, and 
lymphoid tissues and is not yet detectable in plasma, which comprises the eclipse phase. 
Thereafter, HIV RNA becomes detectable in plasma, followed by a predictable sequence of 
detectable markers of HIV infection [45]. 
Based on this sequence, AHI is classified by Fiebig stages using laboratory criteria. In AHI, 
there are sequential assays that test positive: detection of HIV RNA, detection of p24 antigen, anti-
HIV-1 (groups M and O) recombinant gp41 IgM enzyme immunoassay, and Western blot (to HIV-
1 gp160, gp120, p65, p55, gp41, p40, p31, p24, and p18) (Table 1). Fiebig stage V is estimated to 
last up to approximately 90 days post-infection [44]. Fourth-generation antibody-antigen testing is 
standard in the United States and captures Fiebig stages II-VI of AHI, but still misses the pre-p24 
eclipse period of AHI. Given this as well as the fact that newly HIV-infected individuals may 
present later due to the nonspecific symptoms of acute antiretroviral syndrome, diagnosis of AHI 





Table 1. Fiebig stages of acute HIV infection. 
Stage designation Laboratory criteria (additive to prior Fiebig stage) 
Fiebig I RNA+, p24 antigen– 
Fiebig II p24 antigen+, IgM– 
Fiebig III IgM+, Western blot – 
Fiebig IV Western blot indeterminate 
Fiebig V Western blot+ without p31 protein band 
Fiebig VI Western blot+ 
Data from [44]. 
 
Though several routes of HIV transmission are possible (e.g. cervicovaginal, intravenous, 
penile, rectal), CD4+ T cells and Langerhans cells are likely the first targets of HIV infection. Soon 
thereafter, viral replication occurs substantially in the gut-associated lymphoid tissues (GALT) 
within CD4+ T cells expressing high levels of CCR5 coreceptor and then spreads systemically, 
concurrent with a rapid increase in plasma HIV RNA and a steep decline in peripheral CD4+ T 
cells. Indeed, the vast majority of transmitted and founder viruses are shown to be R5-tropic [45]. 
If AHI is left untreated, the CD4 count transiently increases, and later progressively declines, while 
plasma viral load decreases to a steady state set point [45, 47, 48]. 
The immune system rapidly responds to AHI. The frequent occurrence of acute 
antiretroviral syndrome suggests a systemic inflammatory response to AHI. Both soluble and 
cellular markers of immune activation appear within the first few days of HIV infection, including 
acute phase reactants, cytokines, and CD8+ T cell activation [49-51]. Early CD8+ T cell activation 
leads to proliferation that has been shown to improve virological control; however, T cell 
activation after the first few weeks of infection seem to contribute to immune dysfunction [52]. 
From the RV254 cohort of Thai participants with AHI, Fiebig I AHI is associated with lower 
immune activation compared to later Fiebig stages, as measured by soluble CD14 (sCD14), 
CD4/CD8 ratio, and CD8+ T cell activation [53]. Thus, the immune response appears to be 





Additionally, a substantial proportion of CD4+ T cells in the GALT that are depleted during AHI 
are Th17 cells that secrete/respond to IL-17, which are integral to maintaining the integrity of the 
GI tract mucosal barrier. Depletion of Th17 cells in AHI compromises the mucosal barrier, 
resulting in translocation of GI tract microbes and microbial products that contributes to systemic 
inflammation seen in AHI [54]. Finally, immune activation markers in CSF are elevated in a subset 
of individuals with AHI; they include neopterin (marker of macrophage activation) and 
chemokines CXCL10 and CCL2 (immune cell trafficking) [55]. 
Given that immune dysfunction may arise even within early HIV infection, ART initiation 
in AHI continues to be investigated for potential therapeutic benefit. Within the RV254 cohort, 
ART in AHI reduced markers of inflammation (C-reactive protein, sCD14, hyaluronic acid) and 
even normalized some when compared to HIV-negative controls (tumor necrosis factor, soluble 
IL-6 receptor, D-dimer) [56]. Indeed, treatment during the earlier stages of Fiebig I and II AHI 
was found to have a unique benefit compared to that in Fiebig III, in that it restored mucosal Th17 
numbers and polyfunctionality and reversed peripheral and mucosal CD8+ T cell activation [57]. 
However, initiation of ART in Fiebig I does not appear to confer a unique benefit for restoring 
CD4/CD8 ratio when compared to initiation of ART at later Fiebig stages, potentially suggesting 
some degree of irreversible immune activation conferred by AHI [53]. When comparing CSF 
versus plasma concentrations of neopterin (marker of macrophage activation) and the chemokines 
CXCL10 and CCL2 (immune cell trafficking), they remained elevated in plasma but in CSF were 
normalized to levels seen in HIV-negative controls. This suggests a unique benefit of early ART 
initiation for reducing and reversing neuroinflammation [58].  
Studies of AHI and immediate treatment initiation also allow for an assessment of early 





prospect of achieving ART-free HIV remission. The reservoir, as measured by HIV DNA, is 
established in early infection [39, 59]. Reservoir size also increases throughout the stages of AHI. 
Participants identified during Fiebig I had lower total blood and gut HIV DNA compared to those 
in Fiebig stages II and III [39, 53]. Factors impacting viral reservoir size continue to be an area of 
active investigation but include an early CD8+ T cell response [60] as well as timing of ART. If 
early infection is allowed to progress without immediate ART intervention, the HIV reservoir 
dramatically increases and reaches its set point [59]. Early treatment in AHI can significantly 
reduce this reservoir size [39, 59], and one study has shown that this reduction is sustainable over 
three years of ART [61]. Importantly, early treatment alone has not shown to produce ART-free 
HIV remission, even with undetectable HIV RNA or DNA in multiple blood and tissue samples. 
Even with treatment started at Fiebig I and maintained more than two years, participants 
experienced rapid viral rebound just weeks after analytical treatment interruption [62]. One 
participant was able to remain aviremic for more than seven months after analytical treatment 
interruption [63]. Indeed, even ART initiation within as short as 30 hours of life was not enough 
to induce ART-free remission in the Mississippi baby [64, 65]. Looking specifically at the CNS 
compartment, there is evidence of localized benefit of early ART by way of reduced and delayed 
immune activation and HIV-specific antibodies in CSF [58, 66], but there also is evidence of a 
persistent HIV-specific CD8+ T cell response in CSF [67]. It is increasingly thought that immune 
trafficking, signaling, and activation are linked to establishment and persistence of the HIV 
reservoir [54, 68]. CNS reservoir establishment and persistence may be a consequence of immune 
cell trafficking, both early in infection and throughout chronic infection. Because there appear to 





CNS, there may be a unique benefit of early ART in reducing HIV reservoirs in the CNS as 
compared to systemic sites of HIV persistence [40, 69].  
CD4+ T Cell Recovery During Antiretroviral Therapy 
Though ART suppresses ongoing HIV replication in the periphery to undetectable levels, 
up to 30% of ART-treated individuals with chronic HIV infection fail to achieve CD4+ T cell 
counts to a normal level (> 500 cells/mm3) [70]. This phenomenon has been referred to in the 
literature as immunologic non-response, CD4+ T cell response, and immuno-virological 
discordance, and it has been associated with factors including older age, viral hepatitis coinfection, 
lower nadir CD4+ T cell count, longer duration of untreated HIV infection, and worse morbidity 
and mortality [70-74]. Hereafter referred to as poor CD4 recovery, this phenomenon is more likely 
to occur in patients who initiate ART late in the course of infection, often associating with a low 
CD4 nadir [71, 75]. As mentioned earlier, in the initial stages of HIV infection, there is a rapid and 
severe depletion of circulating CD4+ T cells, followed by a spontaneous but temporary recovery 
[48]. Initiation of ART within four months of HIV infection to coincide with this temporary 
recovery period has been associated with improved CD4 recovery [71, 76].  
Although it is uncommon to identify individuals during the narrow window of AHI, the 
RV254/SEARCH 010 study follows a cohort of individuals with AHI in Thailand who are 
identified and begin ART soon after HIV infection. As described earlier, initiation of ART during 
AHI partially resolves systemic inflammation and reduces the viral reservoir [53, 56]. 
Furthermore, initiation of ART during Fiebig stage I results in improved immunological 
reconstitution compared to Fiebig stages II-IV [53]. 
Whether identifying and treating HIV at the earliest stages of infection (within one month) 





recovery has been described in ART initiation within four to six months of infection or 
seroconversion [71, 76, 77]. Whether HIV-associated neuroinflammation or HIV-associated 
neurocognitive or affective symptoms are associated with poor CD4 recovery have yet to be 
examined. 
CSF HIV Escape During Antiretroviral Therapy 
In early HIV infection, central nervous system (CNS) infection can be detected by the 
presence of HIV RNA in the cerebrospinal fluid (CSF) as early as eight days after infection [55, 
78]. Indeed, more than half of RV254 participants with AHI reported neurological symptoms 
within 12 weeks after diagnosis, with half of those occurring before diagnosis and ART initiation 
[79]. Thus, the CNS is affected early in HIV infection, both virologically and clinically. 
Interestingly, virological dynamics between plasma and CSF show that in AHI, CSF HIV RNA is 
consistently lower than concurrent plasma HIV RNA [55]. Given this and the proposed mechanism 
of immune cell trafficking that may introduce HIV into the CNS, it is likely that CSF HIV RNA 
has a delayed appearance behind that in plasma [40]. 
As discussed in the prior section “Acute HIV Infection”, markers of immune activation 
and inflammation appear in the CNS in AHI [55]. Importantly, there are neuroimaging findings, 
specifically magnetic resonance spectroscopy, that are consistent with early CNS inflammation, 
including elevated choline/creatinine that likely represents immune cell activation [55]. However, 
neurofilament light chain (NFL) in CSF, a marker for neuronal injury, was not elevated in AHI 
[80]. It is thus possible that in AHI, the CNS is infected through trafficking of infected immune 
cells or perhaps viral seeding across a compromised blood-brain barrier, resulting in localized 





Rapid initiation of ART suppresses HIV replication in the CNS and reverses neuroinflammation 
[40, 58].  
Importantly, the CNS may continue to be affected uniquely in the phenomenon of CSF 
escape, in which viral presence is undetectable in the periphery due to ART suppression but is 
detectable in CSF. Initially thought to be rare, one study has suggested an incidence rate of up to 
10% of individuals with CSF escape [81]. An area of active investigation, only recently have there 
been international consensus guidelines to provide a clearer definition, which are reproduced in 
Table 2 [82]. CSF escape may vary from asymptomatic to symptomatic, as CSF HIV RNA may 
be detected only incidentally via unrelated lumbar puncture. However, lumbar puncture may also 
be indicated in the work-up of new neurological symptoms in an ART-adherent, previously well-
controlled patient with HIV [83]. Peluso et al presented a case series of ten patients with 
symptomatic CSF escape, wherein new neurologic symptoms (sensory, motor, and/or cognitive) 
prompted lumbar puncture and, for some, neuroimaging and CSF resistance testing.  All patients 
had CSF pleocytosis or elevated CSF protein, and among those who had the studies conducted, 
most had magnetic resonance imaging (MRI) findings (7 of 8) and CSF resistance mutations (6 of 
7). Optimizing the ART regimen clinically improved eight of nine patients [84]. Thus, CSF escape 
encompasses a clinical phenomenon that can have symptomatic impact in some patients, which 
may also be resolvable by treatment optimization. In at least some patients with CSF escape, there 
is evidence of neuroinflammation. Additionally, another potential driver of CSF escape is 
compartmentalized drug resistance secondary to sub-therapeutic levels of antiretrovirals in the 





Table 2. Recommended guidelines for definitions of cerebrospinal fluid escape, from the 
Second Global HIV CSF Escape Consortium in 2017 
1. When plasma HIV RNA is suppressed, the presence of quantifiable HIV RNA in the 
cerebrospinal fluid at any level should be considered cerebrospinal fluid HIV RNA escape 
2. When plasma HIV RNA is detectable, cerebrospinal fluid HIV RNA greater then plasma 
HIV RNA, at any level, should be considered cerebrospinal fluid HIV RNA escape 
3. Defining symptomatic versus asymptomatic cerebrospinal fluid HIV RNA escape should be 
based on patient symptomatology 
4. Cerebrospinal fluid HIV escape should be actively managed in 
symptomatic cases 
Reproduced from [82]. 
 
CSF escape may also be secondary to a superimposed neuroinflammatory or 
neuroinfectious condition [83]. Cases have been described of CSF escape in the context of 
neurosyphilis, varicella zoster virus meningitis, and neuroborreliosis [85-87]. The possibility of 
secondary CSF escape from superimposed neuroinflammation makes it difficult to reconcile 
whether inflammation drives CSF escape via increased immune cell trafficking or blood-brain 
barrier disruption, or whether CSF escape can drive a localized neuroinflammatory response to 
localized viral replication. 
One concern for CSF HIV escape during ART is that even low-level HIV replication in 
CSF has been shown to associate with markers of immune activation and CNS injury. Spudich et 
al characterized a subset of participants in primary HIV infection with CSF HIV RNA < 100 
copies/mL who had increased neuroinflammation, as measured by CSF white blood cells (WBC), 
neopterin, and CXCL10, compared to HIV-negative controls [88]. In a group of patients with < 40 
copies/mL of HIV RNA in both plasma and CSF by standard assays, ultrasensitive assays found 
that those with low-level CSF HIV RNA tended to have higher CSF neopterin [89], even with 
years of suppressive ART. Similarly, low-level detection of CSF HIV associates with 





frank CSF escape (e.g. > 100 copies/mL) may result in new neurological impairment, there is also 
concern for subclinical or low-level CSF escape that is also pathological. 
Finally, one last concern for CSF HIV escape is whether it indicates the presence or long-
term persistence of a CNS reservoir [83]. This is especially relevant in the discussion and progress 
towards achieving ART-free HIV remission, as the CNS reservoir remains an important target. 
One important point to consider is that persistent CSF escape most likely points to HIV replication 
from CNS resident cells, i.e. a reservoir. However, not all cases of CSF escape are persistent; 
indeed some appear to be episodic [91], though this is difficult to know for certain given the paucity 
of longitudinal CSF data [41]. Episodic CSF escape, otherwise called CSF HIV viral blips, could 
stem from CNS reservoirs, but could also be explained by transient immune cell trafficking into 
the CNS that supports local viral replication [41]. Joseph et al investigated cases of CSF escape 
using deep sequencing, identifying one case of a macrophage-tropic, partially drug-resistant, 
genetically diverse escape population likely to stem from CNS reservoirs, and two cases of T cell-
tropic, genetically homogenous escape populations likely to stem from immune cell trafficking 
and transient clonal expansion [92]. 
Given the potential significance of CSF escape for ongoing inflammation and CNS injury 
in the setting of peripheral ART suppression, as well as for pointing to a CNS HIV reservoir, it 
remains unknown whether CSF escape can occur after identifying and treating AHI within the first 
month of infection. Early ART in AHI appears to confer benefit in terms of mitigating 
neuroinflammation and neuronal injury, as described above, but whether it confers a benefit in 
terms of reducing events of CSF escape remains uncertain. Investigating this open question can 





Statement of Purpose 
This thesis encompasses two projects pertaining to immunological reconstitution and 
CNS reservoirs in AHI: to investigate if poor CD4 recovery occurs (Project 1) and if CSF escape 
occurs (Project 2) when ART is started during AHI. We identified pre-ART (baseline) and on-
ART clinical and laboratory parameters associated with poor CD4 recovery, including systemic, 
central nervous system (CNS), and coinfection factors known to associate with CD4 recovery in 
chronic infection. We also identified clinical and laboratory factors associated with CSF escape 




Individuals with AHI identified at the Thai Red Cross AIDS Research Centre (TRC-ARC) 
in Bangkok were enrolled in the ongoing RV254/SEARCH010 study (clinicaltrials.gov 
NCT00796146) [93]. The TRC-ARC is an anonymous voluntary HIV testing and counseling 
center in Bangkok, Thailand. Clients are provided a unique identifier at their first visit, which is 
used for all subsequent visits. Clients also fill out an optional demographic and risk-behavior 
questionnaire. RV254/SEARCH010 is a study within TRC-ARC that identifies clients with Fiebig 
stages I through V AHI, using paired 4th-generation HIV antigen/antibody immunoassay and 
nucleic acid testing (NAT), and offers immediate ART.  
Nonreactive 4th-generation immunoassays had their samples pooled for qualitative NAT 
screening. Pooled samples with reactive NAT testing were deconstructed, and individual samples 
were re-tested to identify HIV-positive samples. HIV-positive samples were tested by quantitative 





asked to enroll in the study. Clients with reactive 4th-generation immunoassay, nonreactive 3rd-
generation immunoassay or nonreactive 2nd-generation immunoassay, and p24 Western blot 
negative or indeterminate were contacted and requested to enroll in the study. All samples were 
tested within 24 hours to quickly identify AHI [93]. One participant who was enrolled as Fiebig V 
was subsequently reclassified to Fiebig VI based on new assay thresholds and was retained in the 
study. 
Duration of infection was estimated based on dates of exposure in the past 30 days. 
Participants voluntarily documented exposure events within the past 30 days. Exposure events 
were stratified according to no risk (no exchange of bodily fluids, non-insertive sex, or contact of 
bodily fluids with intact skin), low risk (receptive oral sex without ejaculation, insertive oral sex, 
or exposure of mucous membranes to bodily fluids), medium risk (anal or vaginal sex with condom 
use regardless of HIV serostatus, receptive condom-less oral sex with male partner with either 
unknown HIV serostatus or positive HIV serostatus with suppressed viral load), or high risk (anal 
or vaginal sex without condom use, receptive condom-less oral sex with male HIV-positive partner 
with detectable or unknown viral load, or injection drug use). The HIV exposure date was 
calculated as the mean date of all exposures in the highest risk category reported by the participant. 
Exposure events within the past 30 to 60 days were considered only if the participant reported no 
sexual activity within the past 30 days, or if the participant tested in Fiebig stages III-V and 
reported high risk exposures in the past 30 to 60 days and lower risk exposures in the past 30 days. 
Participants were offered immediate initiation of ART via an accompanying protocol 
(clinicaltrials.gov NCT00796263). Standard first-line ART through 2016 included efavirenz plus 
two nucleoside reverse transcriptase inhibitors. Efavirenz could be replaced by ritonavir-boosted 





added raltegravir and maraviroc [94]. The majority were switched from efavirenz to dolutegravir 
starting in 2017.  
Participants underwent serial interviews, examinations, and phlebotomy, with optional 
procedures. Clinical and laboratory assessments were performed at days 0, 2, 3, 5, 7, 10, and at 
weeks 2, 4, 8, 12, 16, 20, 24, and every 12 weeks thereafter. Laboratory assessments included 
CD4+ T cell count, CD8+ T cell count, HIV RNA, and complete blood count. Hepatitis B and C 
serology testing was performed every 48 weeks. Infection with hepatitis B or C was confirmed 
with plasma viral load testing. Additional laboratory assessments included biomarkers of 
inflammation and immune activation, as listed below. Optional procedures included lumbar 
puncture, brain MRI/MRS, sigmoid biopsy, leukapheresis, inguinal lymph node biopsy, and 
genital secretions.  
Optional lumbar punctures were obtained at study entry and at weeks 24, 96, and 240. CSF 
studies included cell count, protein, glucose, and HIV RNA. The remaining cell-free CSF was 
stored within six hours of collection at −80°C. 
T1-weighted and T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI brain 
scans were optionally obtained at study entry on the same 1.5T GE scanner, and were 
independently interpreted by two neuroradiologists. 
An optional neuropsychological testing battery was obtained at study entry and weeks 12, 
24, and 96. It consisted of the Grooved Pegboard test in the nondominant hand (fine motor 
function), Color Trails 1 and Trail Making A (psychomotor speed), and Color Trails 2 (executive 
functioning/set-shifting). Raw neuropsychological testing results were standardized to healthy 





mean of z-scores was computed (NPZ-4) for an overall metric of neuropsychological testing 
performance. 
Participants completed the Thai version of the Hospital Anxiety and Depression Scale 
(HADS), a 14-item scale with anxiety and depression subscales of 7 items each. Each item is 
scored from 0 to 3, with a total score range of 0 to 21 per subscale. 
All participants provided written informed consent prior to enrollment in the cohort. The 
research protocol was approved by institutional review boards at Chulalongkorn University 
Hospital, Yale School of Medicine, UCSF, and the Armed Forces Research Institute for Medical 
Sciences. 
Project 1 included all participants who initiated ART between April 2009 and April 2016 
with at least 48 weeks of documented HIV-RNA < 50 copies/mL, regardless of time to 
suppression. Eligible participants were stratified by latest CD4+ T cell count to suboptimal 
recovery (<350 cells/mm3), intermediate recovery (350-499 cells/mm3), and complete recovery 
(≥500 cells/mm3), in agreement with and for appropriate comparison to prior studies of CD4 
recovery in chronic HIV [70]. None of the participants enrolled in analytic treatment interruption 
or interventional substudies before the latest follow-up visit used in the analysis. 
Project 2 included all participants who initiated ART between April 2009 and April 2019 
with paired blood and CSF sampling in at least one visit at study enrollment (baseline), week 24, 
or week 96. CSF escape was defined as paired CSF HIV RNA greater than plasma HIV RNA at 
week 24 or week 96, as per recent international consensus definitions [82]. 
Sampling and Laboratory Testing 
For Project 1, clinical and laboratory parameters were assessed at baseline and latest study 





assessments were examined at a standardized interval of 96 weeks after starting ART. CD4+ T 
cell count was assessed at all available study visits to investigate longitudinal trends. For Project 
2, clinical and laboratory parameters were assessed at baseline, week 24, and week 96.  
CD4+ T cell count was measured by single- and dual-platform flow cytometry (Becton-
Dickinson). HIV RNA in plasma was performed using the COBAS AMPLICOR HIV-1 Monitor 
Test v1.5 or COBAS Taqman HIV-1 Test v2.0 (Roche Molecular Systems). Lower limit of 
quantification for plasma HIV RNA was 50 and 20 copies/mL, respectively, depending on the 
platform used. CSF samples were diluted fourfold for volume requirements for detection of HIV 
RNA, with a lower limit of quantification at 80 copies/mL using the Taqman platform. 
Plasma soluble CD14 (sCD14), intestinal fatty acid binding protein (I-FABP) (R&D 
Systems), and hyaluronic acid (Corgenix) were measured by ELISA. C-reactive protein was 
measured by electrochemiluminescence assay (Meso Scale Discovery). D-dimer was measured by 
enzyme-linked fluorescent assay (bioMerieux). Tumor necrosis factor-alpha (TNF-alpha) and 
high-sensitivity interleukin 6 (IL-6) were measured by the Luminex platform (Millipore). All 
assays for biomarkers were performed in duplicate on cryopreserved acid citrate dextrose plasma 
for research purposes only following a single thaw with the exception of I-FABP (two thaws). 
Anti-hepatitis C antibodies, hepatitis B surface antigen (HBsAg), and anti-HBsAg antibodies were 
measured by chemiluminescent microparticle immunoassay (Abbott). Syphilis testing was 
measured by B VDRL Antigen BD Difco (Becton Dickinson), Macro-Vue RPR Card Tests 
(Becton Dickinson), and Serodia TPPA (Fujirebio Diagnostics). CSF levels of neopterin were 






Data were reported as median (interquartile range, IQR) values, except when otherwise 
indicated. Comparisons between CD4 recovery groups were performed using the Mann-Whitney 
U test or Kruskal-Wallis test for continuous variables, c2 test for categorical variables, and linear 
regression for slope analyses. Slope analyses were performed by assessing CD4 change from 
baseline to week 48 on ART. Multivariate logistic regression analyses were adjusted for baseline 
CD4 count, baseline HIV-RNA, and duration on ART. Statistical tests were two-sided, and 
differences were considered significant at p<0.05. Differences were considered suggestive of a 
trend at p<0.10. Analyses were performed using SPSS Statistics (version 24; IBM), R (version 
3.6.1; R Foundation for Statistical Computing), and Prism (version 7.0; GraphPad) software. 
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Research Centre in Bangkok, Thailand, in August 2019, to review clinical records, collect and 
clean data, and perform statistical analyses. Collaborators participated in study coordination, 
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neuropsychological testing, laboratory testing, and data management. Assays were performed by 
collaborators either locally in Bangkok or at research laboratories in Maryland. This author 
performed all statistical analyses, apart from assistance provided by Suteeraporn Pinyakorn for 





Results: Project 1 
Study Participant Characteristics 
During the RV254/SEARCH010 study period, 304 participants with AHI immediately 
started ART and had documented viral load < 50 copies/mL for at least 48 weeks (Figure 1), of 
whom 79 underwent optional CSF sampling. 96% of enrollees were Thai men, the majority men 
who have sex with men. Median age was 26 years (range 18-57). ART was started at a median 19 
days post-estimated infection (range 1-62). Median latest follow-up visit was at 144 weeks (range 
60-420). 
 
Figure 1. Longitudinal HIV RNA of participants with acute HIV infection. Solid line 
represents the proportion of participants with HIV RNA < 50 copies/mL at each follow-up study 
visit week. Dotted line represents the total number of participants at each study visit week. 
 
CD4+ T Cell Recovery After ART in Acute HIV 
Of the 304 participants, the most recent CD4 count was <350 cells/mm3 (suboptimal 
recovery) in 3.6%, 350-499 cells/mm3 (intermediate recovery) in 14.5%, and ³500 cells/mm3 





























(complete recovery) in 81.9%. Viral load at enrollment, time from HIV transmission to ART 
initiation, week of first documented viral suppression, and Fiebig stage at enrollment did not differ 
between recovery groups (Table 3). Duration of ART was shortest in the intermediate recovery 
group (median 120 weeks, IQR 84-192, p=0.03) but did not differ between suboptimal (156, 84-
180) and complete recovery groups (156, 108-216, p=0.5). Duration of ART was shorter in the 
combined suboptimal and intermediate recovery group versus complete recovery (p=0.01).  
CD4 counts of individuals in the three recovery groups were plotted at each study visit 
week (Figure 2). Using slope analysis, mean (standard deviation) rates of recovery were 3.1 (3.4), 
3.5 (2.1), and 5.5 (4.1) cells/mm3/week for suboptimal, intermediate, and complete recovery 
groups, respectively. Recovery rate in intermediate recovery was significantly slower compared to 
complete recovery (rate difference -2.0 cells/mm3/week, 95% confidence interval [CI] -3.3 to -0.8, 
p=0.002). There was a trend of slower rate in suboptimal compared to complete recovery (rate 
difference -2.4 cells/mm3/week, 95% CI -4.7 to 0.0, p=0.05). There was no difference between 
suboptimal and intermediate recovery groups. Individuals were stratified into groups of low (<350 
cells/mm3), medium (350-499 cells/mm3), and high (≥500 cells/mm3) baseline CD4 count, and 
longitudinal CD4 counts within each group were plotted at each study visit week (Figure 3). 
CD4 count differed by Fiebig stage at enrollment and was highest for Fiebig stage I at 
enrollment (p<0.0001, Figure 4). CD4 count at latest study visit was not different by Fiebig stage 
at enrollment. Change in CD4 count between baseline and latest study visit was different by Fiebig 























Age, years (IQR) 23 (20-30) 26 (23-30) 26 (23-33) 0.3 
Sex, male:female, n 11:0 44:0 237:12 0.3 
Risk behavior, n (%) 
   WSM 
   MSW 
















Thai ethnicity, n (%) 11 (100) 43 (98) 244 (98) 0.9 
Illicit drug use during HIV 
exposure, n (%) 
2 (18) 13 (30) 51 (21) 0.4 
HIV-RNA at enrollment (log10 
copies/mL), median (IQR) 
5.9 (5.4-7.3) 6.1 (5.4-6.9) 5.7 (5.2-6.6) 0.3 
Time to ART initiation (days), 
median (IQR) 
20 (14-23) 21 (15-28) 19 (15-26) 0.6 
1st week of viral suppression, 
median (IQR) 
16 (8-24) 12 (8-24) 12 (8-24) >0.9 
ART duration (weeks), median 
(IQR) 
156 (84-180) 120 (84-192) 156 (108-216) 0.03 
Fiebig stage at enrollment, n 
(%) 
   Stage I 
   Stage II 
   Stage III 
   Stage IV 























Abbreviations: HIV, human immunodeficiency virus; WSM, women who have sex with men; MSW, men who 







Figure 2. Longitudinal CD4+ T cell counts of participants with acute HIV infection according 
to suboptimal, intermediate, and complete recovery groups. (A) Mean CD4+ T cell counts of 
all participants (black) and by suboptimal (red), intermediate (green), and complete recovery (blue) 
groups. Dotted black line represents the total number of participants across all recovery groups at 
each study visit week. B-D, CD4+ T cell counts of participants in suboptimal (B), intermediate 
(C), and complete (D) recovery groups. Solid lines represent the mean CD4+ T cell count at each 
follow-up study visit week. Dashed lines represent the 95% confidence interval of CD4+ T cell 
counts at each study visit week. Dotted black lines represent the total number of participants in 
each respective recovery group at each study visit week. Confidence intervals for panels B-D tend 
to increase over time due to the declining sample size of participants at each subsequent week of 
follow-up visit. 
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Figure 3. Longitudinal CD4+ T cell counts of participants with acute HIV infection according 
to low, medium, and high baseline CD4 count. (A) Mean CD4+ T cell counts of all participants 
(black) and by low (red, baseline CD4 < 350 cells/mm3), medium (green, baseline CD4 350-499 
cells/mm3), and high (blue, baseline CD4 ≥ 500 cells/mm3) baseline CD4 count. Dotted black line 
represents the total number of participants at each study visit week. B-D, CD4+ T cell counts of 
participants with low (B), medium (C), and high (D) baseline CD4 count. Solid lines represent the 
mean CD4+ T cell count at each follow-up study visit week. Dashed lines represent the 95% 
confidence interval of CD4+ T cell counts at each study visit week. Dotted black lines represent 
the total number of participants in each respective group at each study visit week. Confidence 
intervals for panels B-D tend to increase over time due to the declining sample size of participants 
at each subsequent week of follow-up visit. 
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Figure 4. CD4+ T cell count by Fiebig stage at enrollment. Violin plots of CD4 count at baseline 
(A) and at latest study visit (B) by Fiebig stage at enrollment. (C) Violin plot of change in CD4 
count between baseline and latest study visit by Fiebig stage at enrollment. Comparison between 
groups by Kruskal-Wallis test. **** indicates p<0.0001, ns indicates not statistically significant. 
 
Baseline Pre-ART Predictors of CD4 Recovery After ART 
At baseline, CD4 and absolute lymphocyte counts were lower in participants with 
suboptimal compared to complete recovery (CD4 count: median 265 vs 411 cells/mm3, p=0.002, 
Table 4). CD8 count, CD4/CD8 ratio, hemoglobin, and platelet count at baseline were not different 
between suboptimal and complete recovery. 
Given the small size of the suboptimal recovery group and the similar CD4 trajectories of 
the suboptimal and intermediate recovery groups, we combined these two groups and compared 
baseline predictors with complete recovery. CD4/CD8 ratio and CD4+ T cell, total WBC, absolute 
lymphocyte, absolute monocyte, and platelet counts were lower in the combined group compared 
to the complete recovery group at baseline. Intestinal fatty acid binding protein (I-FABP) was 
lower in the combined group compared to complete recovery. Other markers of inflammation were 
similar between these groups (Table 4).  
 





























































Table 4. Pre-ART baseline predictors of CD4 recovery. 














CD4 count (cells/mm3) 265 (91-371) 275 (214-371) 411 (303-533) 0.002 < 0.001 
CD8 count (cells/mm3) 412 (228-575) 448 (298-847) 512 (339-854) 0.09 0.4 
CD4/CD8 ratio 0.67 (0.37-0.94) 0.66 (0.35-0.87) 0.81 (0.47-1.2) 0.4 0.003 
WBC count (× 103 
cells/mm3) 
4.5 (3-5.6) 4.7 (4.0-5.6) 5.5 (4.4-7.0) 0.03 0.003 
Absolute neutrophil count (× 
103 cells/mm3) 
2.84 (1.56-3.52) 2.90 (2.24-3.60) 3.13 (2.18-4.22) 0.3 0.2 
Absolute lymphocyte count 
(× 103 cells/mm3) 
1.06 (0.69-1.48) 1.18 (0.93-1.91) 1.58 (1.21-2.10) 0.003 < 0.001 
Monocyte count (× 103 
cells/mm3) 
0.38 (0.28-0.63) 0.40 (0.31-0.52) 0.52 (0.42-0.66) 0.1 < 0.001 






0.038 (0.018-0.082) 0.9 0.09 
Hemoglobin (g/dL) 15 (14-16) 15 (14-16) 15 (14-16) 0.2 0.2 
Platelet count (× 103/mm3) 215 (167-233) 215 (180-248) 234 (188-296) 0.1 0.01 
sCD14 (µg/L) - 1.3 (1.1-2.3)a 1.6 (1.1-1.9)b - 0.9 
IL-6 (pg/mL) - 0.6 (0.4-1.4)c 0.5 (0.3-0.9)d - 0.3 
Hyaluronic acid (ng/mL) - 17.6 (9.7-30.2)a 18.0 (9.0-32.4)b - 0.96 
Intestinal fatty acid binding 
protein (pg/mL) 
- 738 (343-944)a 1044 (637-1559)b - 0.045 
C-reactive protein (mg/L) - 2.1 (0.5-4.2)a 1.3 (0.7-3.4)b - 0.96 
TNF-alpha (pg/mL) - 1.3 (0.8-2.1)c 1.2 (0.7-2.2)d - 0.9 
D-dimer (ng/mL) - 357 (283-473)a 266 (173-435)b - 0.3 
Median (IQR). 
Abbreviations: CD4, CD4+ T cell; CD8, CD8+ T cell; WBC, white blood cell; sCD14, soluble CD14; IL-6, 
interleukin-6; TNF-alpha, tumor necrosis factor alpha. 
†P-value is for suboptimal recovery vs complete recovery.  
‡P-value is for combined suboptimal & intermediate recovery vs complete recovery. 






CSF sample results for suboptimal (CSF n=3) and intermediate (CSF n=7) recovery groups 
were also combined for comparison to complete recovery (CSF n=69). CSF viral load, WBC count, 
protein, and glucose were not different between the combined and complete recovery groups. 
Baseline CSF neopterin trended in elevation in the combined group (n=10) compared to the 
complete recovery group (n=69, median 2938 vs. 1623 pg/mL, p=0.05, Table 5). Suboptimal 
versus complete recovery groups did not differ on neuropsychological tests (Color Trails 1, Color 
Trails 2, Trail Making A, Grooved Pegboard) or psychiatric indices (Patient Health Questionnaire) 
at baseline (Table 6). Markers for co-infection or exposure to hepatitis B virus, hepatitis C virus, 
and syphilis at baseline were not associated with CD4 recovery (Table 6).  
Table 5. Pre-ART baseline predictors of CD4 recovery, measured in CSF. 
Pre-ART Baseline 
Predictors in CSF 






CSF HIV RNA (log10 
copies/mL) 
3.8 (2.9-4.2) 3.0 (2.0-4.1) 0.3 
CSF WBC count 
(cells/mm3) 
0 (0-0) 0 (0-0) 0.7 
CSF protein (mg/dL) 38 (26-41) 29 (25-35) 0.3 
CSF glucose (mg/dL) 62 (58-66) 61 (57-66) 0.7 
CSF neopterin (pg/mL) 2938 (2069-5310) 1623 (958-3140) 0.05 
Median (IQR). 
Abbreviations: ART, anti-retroviral therapy; CSF, cerebrospinal fluid; WBC, white blood cell. 























0/10 (0) 1/54 (2) 2/248 (1) 0.8 0.5 
Positive anti-HBs, 
n (%) 
5/11 (45) 28/54 (52) 133/249 (53) 0.6 0.8 
Positive HBsAg, n 
(%) 
1/11 (9) 3/55 (5) 15/249 (6) 0.7 0.9 
Reactive VDRL, n 
(%) 
2/10 (20) 7/54 (13) 30/249 (12) 0.5 0.9 
NPZ-4 score 0.007 (-0.7 – 
0.1) 
n=11 
-0.002 (-0.5 – 
0.4) 
n=50 




Total PHQ score 14 (7 – 16) 
n=11 
12 (7 – 15) 
n=50 
9 (6 – 14) 
n=216 
0.2 0.09 
Abbreviations: ART, anti-retroviral therapy; HCV, hepatitis C virus; anti-HBs, hepatitis B surface antibody; 
HBsAg, hepatitis B surface antigen; VDRL, Venereal Disease Research Laboratory test; NPZ-4, 
neuropsychological test z-score in four domains (Color Trails 1, Color Trails 2, Trail Making A, Grooved 
Pegboard); PHQ, Patient Health Questionnaire. 
†P-value is for suboptimal recovery vs complete recovery.  
‡P-value is for combined suboptimal & intermediate recovery vs complete recovery. 
 
On-ART Factors Associated with CD4 Recovery 
The ART regimen initiated at AHI did not predict CD4 recovery (Table 7). By the time of 
most recent study visit, 113 of the 304 participants (37%) were switched to a dolutegravir-
containing regimen after a median (IQR) duration of ART of 145 (107-212) weeks. There was no 
association between switch to dolutegravir and CD4 recovery (not shown). 
As mentioned earlier, assessment of on-ART factors was performed at the latest study visit 
week for each participant, which was at median 144 weeks (range 60-420). Some assays and 
testing, including blood and CSF markers of immune activation, neuropsychological (NP) testing, 
and mood assessments, were only performed at standardized intervals of 24 and 96 weeks. For 






Table 7. Initial ART regimen stratified by CD4 recovery group. 












1 187 1 0 60 249 
Total 1 224 1 1 77 304 
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; LPV, lopinavir; r, ritonavir; EFV, efavirenz; RAL, 
raltegravir; MVC, maraviroc. 
Fisher’s exact test, p=0.1. 
 
On ART, CD8+ T cell count and CD4/CD8 ratio were lower in suboptimal compared to 
complete recovery (median 318 vs 621 cells/mm3, IQR 279-628 vs 490-843, p=0.001 and median 
1.05 vs 1.18, IQR 0.47-1.20 vs 0.91-1.48, p=0.047, respectively) (Table 8). Additionally, 
hemoglobin was higher in suboptimal compared to complete recovery. Platelets were diminished 






Table 8. On-ART variables associated with CD4 recovery. 














CD8 count 318 (279-628) 460 (359-600) 621 (490-843) 0.001 < 0.001 
CD4/CD8 ratio 1.05 (0.47-1.20) 0.95 (0.76-1.16) 1.18 (0.91-1.48) 0.047 < 0.001 
WBC count (× 103 
cells/mm3) 
4.88 (4.68-6.25) 4.99 (4.36-5.74) 6.13 (5.34-7.27) 0.02 < 0.001 
Absolute neutrophil count 
(× 103 cells/mm3) 
3.37 (2.52-4.45) 2.92 (2.27-3.57) 3.23 (2.48-4.21) 0.9 0.07 
Absolute lymphocyte count 
(× 103 cells/mm3) 
0.99 (0.91-1.40) 1.46 (1.24-1.67) 2.19 (1.85-2.48) 2 × 10-7 < 0.001 
Monocyte count (× 103 
cells/mm3) 
0.41 (0.36-0.64) 0.41 (0.35-0.51) 0.51 (0.40-0.62) 0.3 0.001 
Eosinophil count (× 103 
cells/mm3) 
0.13 (0.09-0.19) 0.13 (0.09-0.20) 0.13 (0.08-0.24) 1.0 0.7 
Hemoglobin (g/dL) 
 
15.5 (14.5-16.4) 15.1 (14.4-15.8) 14.7 (14.0-15.6) 0.02 0.04 
Platelet count (× 103/mm3) 223 (185-283) 252 (218-277) 273 (237-313) 0.03 0.002 
sCD14 at week 96 (µg/L) - 1.7 (1.6-1.8)g 1.1 (1.0-1.2)h - 0.008 
IL-6 at week 96 (pg/mL) - 0.13 (0.11-0.56)i 0.56 (0.14-0.97)j - 0.04 
Hyaluronic acid at week 96 
(ng/mL) 
- 15.1 (13.6-21.9)g 11.8 (9.0-18.9)h - 0.4 
Intestinal fatty acid binding 
protein at week 96 (pg/mL) 
- 1533 (1212-2058)g 2953 (1366-3823)h - 0.3 
C-reactive protein (mg/L) - 0.22 (0.19-0.54)g 0.49 (0.19-1.08)h - 0.7 
TNF-alpha (pg/mL) - 0.93 (0.40-16.13)i 1.61 (0.25-4.28)j - 0.6 
D-dimer (ng/mL) - 190 (179-401)g 138 (102-256)h - 0.3 
Median (IQR). Measurements were performed at latest study visit unless otherwise indicated. 
Abbreviations: CD4, CD4+ T cell; CD8, CD8+ T cell; WBC, white blood cell; sCD14, soluble CD14; IL-6, 
interleukin-6; TNF-alpha, tumor necrosis factor alpha. 
†P-value is for suboptimal recovery vs complete recovery.  
‡P-value is for combined suboptimal & intermediate recovery vs complete recovery. 






After combining suboptimal and intermediate recovery groups, we identified on-ART 
factors that differed between the combined and complete recovery groups (Table 8). Consistent 
with the differences between suboptimal and complete recovery, CD8 count, CD4/CD8 ratio, and 
WBC count were lower in the combined group compared to complete recovery. On-ART 
hemoglobin was higher in the combined group, and platelet count was lower. Absolute lymphocyte 
and monocyte counts were lower in the combined group. Serum sCD14 at week 96 was elevated 
and IL-6 was lower in the combined group. 
Optional CSF sample size during ART was too small to assess associations between 
neuroinflammatory markers and CD4 recovery. Suboptimal and complete recovery did not differ 
in neuropsychological test performance or psychiatric indices at 96 weeks of ART (Table 9). On 
ART, markers for co-infection or exposure to hepatitis B virus, hepatitis C virus, and syphilis were 

























0/2 (0) 1/15 (7) 1/49 (2) 0.8 0.4 
Positive anti-HBs, 
n (%) 
2/2 (100) 14/16 (88) 42/50 (84) 0.5 0.7 
Positive HBsAg, n 
(%) 
0/2 (0) 1/16 (6) 8/49 (16) 0.5 0.3 
Reactive VDRL, n 
(%) 
0/1 (0) 4/9 (44) 16/40 (40) 0.4 0.8 
NPZ-4 score at 
week 96 
0.6 (-0.04 – 
0.8) 
n=7 
0.5 (-0.04 – 
0.9) 
n=33 
0.5 (0.03 – 1) 
n=183 
0.6 0.6 
Total PHQ score at 
week 96 
5 (1 – 8) 
n=7 
4 (1 – 8) 
n=33 
5 (2 – 8) 
n=183 
0.9 0.4 
Abbreviations: ART, anti-retroviral therapy; HCV, hepatitis C virus; anti-HBs, hepatitis B surface antibody; 
HBsAg, hepatitis B surface antigen; VDRL, Venereal Disease Research Laboratory test; NPZ-4, 
neuropsychological test z-score in four domains (Color Trails 1, Color Trails 2, Trail Making A, Grooved 
Pegboard); PHQ, Patient Health Questionnaire. 
†P-value is for suboptimal recovery vs complete recovery.  
‡P-value is for combined suboptimal & intermediate recovery vs complete recovery. 
 
 
Independent Effect of Pre- and On-ART Factors on CD4 Recovery 
We used a multivariate logistic regression model to adjust for duration of ART, baseline 
HIV-RNA, and baseline CD4 count (Table 10). After adjustment, participants with baseline 
CD4/CD8 ratio < 1 were more likely to have poor CD4 recovery < 500 cells/mm3 (odds ratio [OR] 
3.2, 95% confidence interval [CI] 1.4-8.4, p=0.01). Participants with baseline I-FABP < 1000 
pg/mL were more likely to have poor CD4 recovery (OR 13.4, 95% CI 1.9-276.4, p=0.02). Those 
with baseline CSF neopterin > 1600 pg/mL had no different odds for poor CD4 recovery after 





per mm3 were more likely to have poor CD4 recovery after adjustment (OR 3.5, 95% CI 1.2-15.3, 
p=0.04). 
After adjustment, odds of poor CD4 recovery were higher in participants with on-ART 
CD4/CD8 ratio < 1 (OR 2.4, 95% CI 1.3-4.6, p=0.007), CD8 count < 500 cells/mm3 (OR 3.1, 95% 
CI 1.6-6.0, p=0.0005), hemoglobin > 14.8 mg/dL (OR 2.0, 95% CI 1.0-4.0, p=0.04), and platelet 
count < 300,000 per mm3 (OR 3.6, 95% CI 1.4-11.1, p=0.01). Participants with sCD14 > 1.8 µg/L 
had no different odds for poor CD4 recovery (p>0.9). Participants with IL-6 < 0.2 pg/mL were 






Table 10. Factors Associated with CD4 Recovery < 500 cells/mm3 
 Univariate Multivariate 
Characteristic OR (95% CI) p-value OR (95% CI) p-value 
Baseline CD4 count 
   <350 cells/mm3 
   350-499 cells/mm3 





< 0.001 - - 
ART duration 
   48-119 weeks 
   120-155 weeks 





0.02 - - 
Baseline HIV-RNA 
   <106 copies/mm3 




0.2 - - 
Baseline CD4/CD8 ratio 
   <1 









   <1000 pg/mL 








Baseline CSF neopterin 
   <1600 pg/mL 








Baseline platelet count 
   <300,000 per mm3 








On-ART CD4/CD8 ratio 
   <1 








On-ART CD8 count 
   <500 cells/mm3 









   <14.8 mg/dL 








On-ART platelet count 
   <300,000/mm3 








sCD14 at week 96 
   <1.8 µg/L 




0.03 - 1.0 
IL-6 at week 96 
   <0.2 pg/mL 








Multivariate models were adjusted for duration of ART, baseline HIV-RNA, and baseline CD4 count. 






Results: Project 2 
Study Participant Characteristics 
During the RV254/SEARCH010 study period, 204 participants with AHI immediately 
started ART and had paired blood and CSF sampling in at least one visit at baseline, week 24, or 
week 96. 98% of enrollees were Thai men, the majority men who have sex with men. Median 
age was 26 years (range 18-60). At enrollment, participants were mostly in Fiebig stage III, with 
median CD4+ T cell count 386 cells/mm3 (range 91-1302) and median plasma HIV RNA 5.87 
log10 copies/mL (range 2.43-7.89). ART was started at a median 19 days post-estimated infection 
(range 3-49). 
At baseline, 126 of 165 participants (76%) had quantifiable CSF HIV RNA with median 
CSF HIV RNA 3.13 log10 copies/mL (range <1.90-6.61). There were no cases where plasma 
HIV RNA exceeded the paired CSF HIV RNA level. At week 24, of 90 available participants 
with paired blood and CSF samples, two participants (2%) had quantifiable CSF HIV RNA. At 
week 96, of 55 available participants with paired blood and CSF samples, one participant (2%) 
had quantifiable CSF HIV RNA (Figure 5). 
At week 24, of the four cases with detectable CSF HIV RNA, one met criteria for CSF 
escape, with plasma HIV RNA < 50 copies/mL and CSF HIV RNA at 2.50 log10 copies/mL. At 
week 96, the one case of detectable CSF HIV RNA did not meet criteria for CSF escape. All 
other cases of detectable CSF HIV RNA were associated with plasma virological failure with 





Table 11. Characteristics of participants treated in acute HIV infection with paired blood 
and CSF samples at weeks 0, 24, and 96. 








Age at enrollment 
(range) 
26 (18-60) 26 (18-60) 27 (18-60) 28 (18-60) 
Male, n (%) 199 (98) 160 (97) 86 (96) 53 (96) 
Risk behavior, n (%) 
   WSM 
   MSW 

















Fiebig stage at 
enrollment, n (%) 
   Stage I 
   Stage II 
   Stage III 
   Stage IV 
   Stage V 





























Time to ART 
initiation (days), 
median (range) 













515 (102-4556) 575 (178-
1352) 
628 (260-1575) 










Proportion of plasma 
HIV RNA < 50 
copies/mL, n (%) 
0 (0) † 
 
0 (0) 86 (96) 53 (96) 








Proportion of CSF 
HIV RNA < 80 
copies/mL, n (%) 






CSF viral escape, n 
(%) 
- - 1 (1) 0 (0) 
Abbreviations: HIV, human immunodeficiency virus; WSM, women who have sex with men; MSW, men who 
have sex with women; MSM, men who have sex with men; CSF, cerebrospinal fluid. 







Figure 5. Paired blood and CSF HIV RNA at weeks 0, 24, and 96. Medians and interquartile 
ranges are indicated by black bars. Dashed lines represent paired blood and CSF HIV RNA from 
participants who had either blood or CSF HIV RNA greater than the respective limit of 
quantitation at week 24 or 96. 
 
Clinical Course of CSF Escape During Treatment in Acute HIV Infection 
Of 204 eligible participants, one participant at week 24 post-treatment initiation met 
criteria for CSF escape. This is a 23-year-old male university student who identifies as bisexual, 
who initially presented with acute retroviral syndrome. His past medical history includes 
migraines and dengue fever. Three months before his presentation with acute HIV infection, he 
was treated for chlamydia and gonorrhea infection. He denied alcohol, tobacco, and other drug 
use. He was diagnosed with acute HIV infection in Fiebig stage IV at estimated 21 days post 
infection and was immediately started on efavirenz, tenofovir, and emtricitabine. Plasma HIV 





























Figure 6. Clinical measurements and neuropsychological testing for the case of CSF escape 
in AHI. A) Longitudinal blood and CSF HIV RNA for the participant with CSF escape 
identified at week 24. B) CD4+ and CD8+ T cell counts (left axis) and NPZ-4 score (right axis) 
for the participant during treatment for acute HIV infection. 
 
This participant had no study lumbar punctures performed other than that at week 24. 
CSF white blood cell count was 4 cells/mm3, protein 30 mg/dL, and glucose 62 mg/dL. The 
participant did not endorse any neurological symptoms at week 24. An MRI was performed at 
this time, which showed a small nonspecific hyperintense focus in the right high frontal white 
matter. The participant also underwent neuropsychological testing at weeks 0, 12, 24, and 96 
(Figure 6). At week 12, the participant scored an NPZ-4 score of 1.76 standard deviations below 
the reference population. At all other time points, NPZ-4 scores were unremarkable. 
After 76 weeks on ART, this participant was transitioned to dolutegravir, abacavir, and 
lamivudine per the study protocol, which was unrelated to the CSF findings from week 24. 
At time of treatment initiation, the participant had a nonreactive VDRL. No VDRL was 


















































Discussion        
Consistent with many other studies emerging from the RV254/SEARCH010 cohort of 
participants with AHI, prompt treatment initiation in the earliest stages of HIV infection appears 
to confer unique immunologic and virological benefits that mitigate the immune dysfunction and 
reservoir establishment seen in treated chronic HIV infection. Not only does early treatment in 
AHI reduce inflammation [56], it improves immunological reconstitution as measured by CD4+ 
T cell recovery. Early ART may also reduce the degree of HIV persistence specifically in the CNS 
compartment, given the very low rate of CSF escape observed in tandem with a prior report of 
normalization of neuroinflammation [58]. 
CD4+ T Cell Recovery in Acute HIV Infection 
We found that suboptimal CD4 recovery occurs in a small subset of individuals despite 
treatment in the earliest stages of AHI. Whereas 70-85% of individuals with chronic HIV infection 
had CD4 recovery to >350 cells/mm3 after ART, we observed a larger proportion (96.4%) in AHI 
[70]. A larger proportion of individuals were categorized as intermediate responders (CD4 count 
350-499 cells/mm3) as compared to suboptimal responders (<350 cells/mm3). Prior work has 
identified determinants of CD4 recovery in early seroconversion, though in the setting of delayed 
ART initiation [76, 96]. To our knowledge, our study is the first to examine determinants of CD4 
recovery with immediate ART initiation in the earliest stages of HIV infection. Furthermore, few 
studies have identified determinants of CD4 recovery in chronic HIV infection in an Asian 
population, and none in early seroconversion or primary HIV infection to our knowledge [97-99].  
The degree of lymphatic tissue fibrosis has been shown to correlate with CD4 recovery 
[19, 100]. As an indicator of a systemic profibrotic state, hyaluronic acid was lower in treated AHI 





controls [56]. Taken together, immediate ART initiation in AHI may limit the extent of lymphatic 
tissue fibrosis compared to that seen in chronic HIV infection, which may explain the lower 
proportion of suboptimal CD4 recovery in AHI. 
When examining the suboptimal and intermediate recovery groups throughout the course 
of treatment (Figure 2), CD4 count trajectories are similar. Additionally, though not apparent in 
the aggregate analysis in Figure 2, some individuals with intermediate recovery appear to have 
transient decreases in CD4 count below 350 cells/mm3, and may in fact sustain an overall CD4 
response around or above the threshold of 350 cells/mm3. Thus, differences between the combined 
suboptimal and intermediate recovery group versus complete recovery are more stark and reveal a 
state of perturbed immunological recovery as compared to differences between suboptimal versus 
intermediate recovery. 
Poor CD4 recovery (< 500 cells/mm3) is associated with nadir CD4 count, and thus 
increases from substantially low nadir may not be captured using an absolute threshold as a 
definition of CD4 recovery. However, our slope analyses show that individuals with complete 
recovery have a higher recovery rate over a fixed time interval of 48 weeks, indicating greater 
absolute and relative increases in CD4 count. Other definitions of CD4 recovery have accounted 
for low nadir, such as an increase of CD4 count ≥ 30% from baseline [101]. We used prior 
definitions of CD4 recovery as absolute thresholds ≥ 350 or ≥ 500 cells/mm3 to allow for direct 
comparison to results in chronic and primary HIV infection. Furthermore, absolute CD4+ T cell 
count during treated HIV infection is a critical clinical measure for risk of opportunistic infections. 
Consistent with a prior description of our cohort, individuals diagnosed and started on ART 
at Fiebig stage I have a higher baseline CD4 count compared to stages II-IV, with normalization 





I have a lower absolute CD4 increase compared to other stages, suggesting that CD4 decline to 
nadir occurs at later Fiebig stages but is reversible with immediate ART initiation. Strategically 
timing earlier ART initiation during an interval of CD4 recovery has been associated with better 
long-term CD4 recovery [71, 72]. Conversely, ART initiation during an interval of CD4 decline is 
associated with poor CD4 recovery [102], suggesting that strategic timing of early ART must 
consider not only nadir CD4 count but also the dynamics of pre-ART CD4 recovery. However, 
initiation of ART in Fiebig stages II-IV did not affect on-ART CD4 count, suggesting that ART 
initiation in AHI does not need to be strategically timed and should be prompt. 
Interestingly, our study showed that lower CD8 count during treatment, but not at baseline, 
was associated with poor CD4 recovery, consistent with a previous report [103]. This may indicate 
suppression of thymic output that has been observed to occur in the setting of poor CD4 recovery 
[104]. However, another study found that higher baseline CD4 count and lower CD8 count were 
independently associated with improved CD4 recovery [105]. The CD8 count may thus be 
interpreted as an indicator of thymic output as well as of immune activation. 
Poor CD4 recovery was independently associated with lower CD4/CD8 ratio both at 
baseline and during treatment in AHI. Reduced CD4/CD8 ratio has been found to be a marker for 
immune dysregulation and activation in the setting of HIV infection that has been associated with 
an increased risk for non-AIDS related morbidity and mortality, including age-related 
inflammation and cardiovascular disease [28, 106, 107]. Despite initiating ART at the earliest 
possible stages of infection, low pre-ART CD4/CD8 ratio remained low on treatment and is a 
predictor for poor CD4 recovery. For our group of poor responders treated during AHI, CD4/CD8 
ratio at baseline was higher than in participants treated during chronic HIV infection, reflecting 





primary versus chronic HIV infection leads to a higher frequency of CD4/CD8 ratio > 1, with 
higher CD4/CD8 ratio at baseline associated with a lower risk of poor CD4 recovery [72]. An 
overall faster time to treatment initiation results in improved CD4/CD8 ratio [108]. Interestingly, 
despite the rapid initiation of ART in early AHI, other markers of chronic inflammation persist in 
the RV254/SEARCH010 cohort [56]. 
We analyzed markers for microbial translocation and systemic inflammation, finding 
elevated sCD14 in suboptimal CD4 responders after treatment. However, sCD14 did not appear to 
be independently associated with CD4 recovery after controlling for duration of ART, baseline 
CD4 count, and baseline HIV-RNA. Some prior studies show increased sCD14, its ligand 
lipopolysaccharide (LPS) [109], bacterial 16S ribosomal DNA [110], or neutrophil infiltration 
[111] in poor compared to complete CD4 recovery, while others find no differences [101]. No 
differences were detected in hyaluronic acid or in systemic inflammatory markers CRP, TNF-
alpha, and D-dimer [101]. Surprisingly, in our study IL-6 was elevated in complete recovery. 
Elevated IL-6 has been associated with increased risk of HIV-associated opportunistic disease 
[12]. Plasma I-FABP at baseline was higher in complete recovery, suggesting increased enterocyte 
turnover, contrary to prior findings [111]. However, in our multivariate model, we report an odds 
ratio for I-FABP with a large margin of error, suggesting this may be a spurious association. 
Platelet counts were lower in poor compared to complete recovery both at baseline and 
after ART, consistent with a prior study [112]. HIV-associated thrombocytopenia has several 
possible mechanisms, including immune-mediated thrombocytopenia via immune complexes 
composed of antibodies cross-reactive to HIV and platelet antigens, decreased platelet survival, 
decreased production, and infection of megakaryocytes [113]. With concurrent thrombocytopenia, 





hematopoiesis. However, there was no association between neutrophil count and CD4 recovery. 
Given that both T lymphocytes and monocytes are natural hosts for HIV infection and replication, 
it cannot be excluded that poor CD4 recovery may reflect persistent HIV infection and subclinical 
replication in both T lymphocytes and monocytes that suppresses their cell counts. A higher 
hemoglobin was observed in suboptimal versus complete recovery post-ART, contrary to other 
reports [114]. 
Poor CD4 recovery trended towards association with neuroinflammation at baseline, as 
measured by CSF neopterin. However, when controlling for confounders, there was no 
independent association between CSF neopterin and CD4 recovery. To our knowledge, this is the 
first study assessing the association between neuroinflammation and impaired CD4 recovery, 
though other CNS biomarkers have been associated with CD4 recovery [115]. Elevated CSF 
neopterin has been associated with CSF HIV-RNA and neurological complications of HIV 
infection [116]. Elevated plasma neopterin has been associated with poor CD4 recovery in treated 
HIV infection [117]. Suboptimal CD4 recovery may reflect not just a systemic inflammatory state 
but also a localized neuroinflammatory state, which may have implications for neurological 
outcomes in poor responders. Further work is needed to investigate associations between CD4 
recovery and localized inflammation. 
We did not find an association between CD4 recovery and coinfection with syphilis, 
hepatitis B virus, or hepatitis C virus. Our study may not be sufficiently powered to detect an 
association between CD4 recovery and HCV coinfection, given the low number of positive anti-
HCV samples. Some studies have not shown an association between HBV coinfection and CD4 
recovery [118], while others have [119]. Likewise, HCV coinfection has been associated with poor 





A subset of participants was assessed for CD4+ and CD8+ T cell activation by flow 
cytometry of CD38+ T cell subsets. However, sample sizes were too low to assess for an 
association between immunological response and CD38+ expression. CD38+ expression in CD8+ 
T cells has been associated with a faster rate of CD4+ T cell decline in untreated individuals with 
HIV [122]. Additionally, higher expression of immune checkpoint receptor and exhaustion marker 
PD-1 on both CD4+ and CD8+ T cells has been associated with lower CD4 count at baseline and 
after treatment [24, 123]. This was not assessed in this study of acute HIV infection and is a target 
for future investigation. Further work is also needed to assess whether expression of IL-7 receptor, 
regulatory T cell phenotype, and inflammasome upregulation is associated with immunological 
response in acute HIV infection, as described in treated chronic HIV infection [124-126]. 
Our study has several limitations. On-ART factors were measured at the week of the latest 
available study visit, which was lower in the combined suboptimal and intermediate recovery 
group compared to complete recovery. Thus, the overall longer treatment duration in the complete 
recovery group possibly confounds the finding of improved CD4+ T cell gains. However, our 
slope analysis examines rate of recovery over a fixed time interval, showing that the complete 
recovery group exhibits both higher and faster CD4 recovery. Furthermore, we identified pre- and 
on-ART factors independently associated with poor CD4 recovery < 500 cells/mm3 when adjusting 
for duration of ART, as well as baseline CD4 count and HIV-RNA. Our study did not have 
sufficient numbers of lumbar punctures after 48 weeks of ART and thus cannot assess the degree 
of neuroinflammation after ART in poor responders. The participants in this study are young and 
may have a lower baseline inflammatory state due to young age. Finally, the HIV-uninfected Thai 
population have a lower CD4+ T cell count reference range compared to predominantly white or 





CSF Escape in Acute HIV Infection 
We found that after immediate ART initiation in acute HIV infection, there is a very low 
incidence of CSF escape of 1% after 24 weeks and 0% after 96 weeks. Moreover, the singular case 
of CSF escape identified in our study population was at a low CSF viral load of 316 copies/mL 
and was not associated with any neurological findings or dysfunction. Prior studies have identified 
an incidence rate of up to 10% for CSF escape in the setting of treated chronic HIV infection [81], 
though a follow-up study by the same authors suggested that many of these cases of detectable and 
quantifiable CSF HIV RNA are likely better described as CSF viral blips since the CSF viral loads 
mostly are not repeatedly elevated on longitudinal measurements [91]. This episodic CSF viral 
blip may be mechanistically due to cell trafficking into the CNS, resulting in either HIV release or 
transient viral replication [41]. Thus, it remains fairly likely that this case of asymptomatic 
quantifiable CSF HIV RNA paired with undetectable plasma HIV RNA can be considered a CSF 
viral blip. This may be further corroborated by the lack of CSF pleocytosis. Of note, even with 
CSF viral blips, there may be an association between low-level CSF HIV RNA and increased 
neuroinflammation as measured by elevated CSF neopterin levels [91]. 
An additional consideration is the possibility that this singular case represents secondary 
CSF escape, given the nonreactive VDRL at baseline and the reactive VDRL at week 96. Although 
we cannot know when this participant was infected with syphilis, an infection at week 24 cannot 
be excluded as a possible contributor for CSF escape secondary to neurosyphilis. In secondary 
CSF escape, elevated CSF HIV RNA is thought to be due to a superimposed infection or 
inflammatory process causing increased immune cell trafficking into the CNS, which results in 
localized viral replication detectable in CSF [83]. Again, the lack of CSF pleocytosis speaks 





Prior characterizations of this unique AHI cohort have described baseline characteristics 
of early CNS infection. At baseline, most of our participants had detectable HIV RNA in the CSF, 
and none had CSF HIV RNA greater than that in plasma [55]. AHI individuals with a higher CSF 
HIV RNA relative to plasma HIV RNA have a greater degree of systemic inflammation as 
measured by CD4/CD8 ratio and a greater degree of neuroinflammation as measured by CSF 
neopterin, soluble CD163, IL-6, and sCD14 [128]. From our results, CSF HIV RNA is almost 
always suppressed to undetectable levels when initiating ART in AHI with only one case of CSF 
escape. Further work is needed to characterize whether CSF escape in AHI is associated with 
neurological or systemic inflammation. Additionally, since the incidence of CSF escape has been 
associated with longer time on ART in chronic infection [81], long-term follow-up of this cohort 
is necessary to verify that CSF escape remains rare in treated AHI. The rarity of CSF escape in 
treated AHI may point to a benefit in very early treatment in terms of reducing CNS persistence 
and viral reservoirs, though further investigation is needed [40].  
This study has several limitations. This singular case of CSF escape was identified in a 
participant who to date has undergone only one study lumbar puncture, with no CSF samples prior 
to ART initiation nor at any other study visit. Thus, it is impossible to determine whether the 
quantifiable CSF HIV RNA at week 24 has been sustained and to distinguish between persistent 
CSF escape and a CSF viral blip. The level of 316 copies/mL is too low to perform resistance 
testing using available assays, but further testing could be useful in determining whether selection 
for drug resistance is driving this case of CSF escape and determining any degree of 
compartmentalization between blood and the CNS. Further testing could also assess the virological 
phenotype of this CSF escape population, namely its propensity to infect macrophages (M-tropic) 





is produced by CNS reservoirs versus transient immune cell trafficking [41]. We did not measure 
any other markers in CSF, such as neopterin and sCD14, in this participant. Additionally, with 
only one case of CSF escape, we cannot draw any statistically significant associations with markers 
of neuroinflammation or systemic inflammation. In the cohort at large, markers of immune 
activation in CSF but not plasma normalize after 96 weeks of ART [58]. Finally, due to sample 
dilution for volume requirements for CSF, the lower limit of quantification of HIV RNA differs 
between CSF and plasma, and thus our study cannot capture very low-level CSF HIV RNA < 80 
copies/mL that may represent cases of CSF escape or CSF viral blips. Recent work has 
demonstrated that even low-level CSF HIV RNA < 20 copies/mL associates with decreased blood-
brain barrier integrity and executive function [90]. 
 
Conclusions 
In conclusion, suboptimal CD4 recovery following initiation of ART during AHI is low (< 
5%) compared to chronic HIV infection and is characterized by a low CD4 count at baseline and 
persistent low CD8 count during treatment. Poor recovery is also associated with systemic 
inflammation during treatment. CSF escape is rare (1%) following initiation of ART during AHI. 
Future work should be directed at determining whether ART should be initiated as early as possible 
in AHI versus strategic timing of ART within AHI to coincide with spontaneous CD4 recovery in 
order to optimize long-term CD4 recovery [71]. Future work should also corroborate the low 
incidence of CSF escape over longer follow-up > 96 weeks and investigate the virological drivers 
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